Becton, Dickinson and Company

Becton, Dickinson and Company

BDX·NYSE

$149.08

+3.2%
HealthcareMedical - Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

At a Glance

Live Snapshot
Market Cap$54.01B
EPS5.8400
P/E Ratio25.53
Earnings Date08/06/2026

bdx

Sales/Maturities of Investments

Last Annual Value

422.00M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

-7%

Becton, Dickinson and Company

Becton, Dickinson and Company Competitors Analysis of Sales/Maturities of Investments

BDX · NYSE
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
422.00M
N/AN/A-5.2% 
202.00M
91.0%33.9%0.8%
RMD logo
ResMed Inc.
NYSE:RMD
0.00
N/AN/AN/A
0.00
N/AN/AN/A
8.00M
17.0%-7.8%23.1%
2.00M
N/A-16.7%-26.1%
2.88B
59.0%40.3%10.2%
2.06B
27.1%25.8%18.9%
Becton, Dickinson and Company

Becton, Dickinson and Company Fair Value Envelope

BDX · NYSE

Our analysis suggests that BDX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $149.08, this represents a potential HIDDEN relative to our calculated worth for Becton, Dickinson and Company.

Intrinsic Value
Current Price: $149.08